Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(2):121-124
DOI: 10.5428/pcar20190211
Research advances in drug delivery system of cabazitaxel for treatment of patients with prostate cancer
1. WAN Zhong1(1.Department of Urology,Changzheng Hospital,Navy Military Medical University,Shanghai 200003,China smmuwz@126.com)
2. SUN Zhiguo2( 2.Teaching and Research Section of Pharmaceutics,School of Pharmacy,Navy Military Medical University,Shanghai 200433,China )
3. LU Ying2( 2.Teaching and Research Section of Pharmaceutics,School of Pharmacy,Navy Military Medical University,Shanghai 200433,China )
4. WANG Linhui1(1.Department of Urology,Changzheng Hospital,Navy Military Medical University,Shanghai 200003,China wanglinhuicz@163.com)
ABSTRACT  Cabazitaxel is a new taxane-based anti-tumor drug,which has a significant effect on hormone refractory metastatic prostate cancer patients who are ineffective to docetaxel. Although cabazitaxel is used as a second-line clinical drug,it has great application potential due to its low adhesion to P-glycoprotein and good pharmacokinetic characteristics. In recent years,researchers are paying more attention to it. Based on the research progress achieved both at home and abroad and with the pharmacological effects and adverse drug reactions as the starting point,a comprehensive review was made in the drug delivery system of cabazitaxel for treatment of prostate cancer.
Welcome to PCAR! You are the number 213 reader of this article!
Please cite this article as:
WAN Zhong1,SUN Zhiguo2,LU Ying2,WANG Linhui1,. Research advances in drug delivery system of cabazitaxel for treatment of patients with prostate cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 121-124.
References:
1. Siegel R L,Miller K D,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
2. YE Dingwei,ZHU Yao.Epidemiology of prostate cancer in China:an overview and clinical implications[J].Chin J Surg,2015,53(4):249-252.In Chinese with English abstract.
3. DONG Juan.Research advances in the mechanism of hormone-refractory prostate cancer resistance to docetaxel treatment[J].Chin J Urol,2011,32(2):138-140.In Chinese.
4. Branch of Promotive Urinary System Health,China Medicinal Promotive Association;Branch of Urology,China Investigative Type Hospital Association.Consensus on the safety of chemotherapy for prostate cancer[J].J Mod Urol,2018,23(2):85-92. In Chinese.
5. ZHOU Aiping,FANG Hong,LI Changling,et al.Cabizitaxel,a novel drug for castration-resistant prostate cancer[J].Chin J New Drugs,2013,22(19):2229-2231.In Chinese with English abstract.
6. HAO Bin,MA Zhifang.Chemotherapy for castration-resistant prostate cancer and its new progress[J].J Clin Urology(China),2015,30(1):83-87. In Chinese with English abstract.
7. ZHUANG Bo,DU Liang,XU Hongxia,et al.Self-assembled micelle loading cabazitaxel for therapy of lung cancer[J].Int J Pharm,2016,499(1-2):146-155.
8. Clèment-Zhao A,Auvray M,Aboudagga H,et al.Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer[J].BJU Int,2018,121(2):203-208.
9. Oudard S,Fizazi K,Sengelv L,et al.Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer:a randomized phase Ⅲ trial-FIRSTANA[J].J Clin Oncol,2017,35(28):3189-3197.
10. YU Xiaojie,WU Yibo,MAO Jing,et al.Poly(ethylene glycol)-b-poly(lactic acid) terminal modification and application in cabazitaxel-loaded system[J].Polym Mater Sci Engin,2018,34(6):42-48.In Chinese with English abstract.
11. HAN Xiaoxiong,CHEN Dan,SUN Jing,et al.A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time[J].J Biomater Sci Polym Ed,2016,27(7):626-642.
12. Aydin O,Youssef I,Yuksel Durmaz Y,et al.Formulation of acid-sensitive micelles for delivery of cabazitaxel into prostate cancer cells[J].Mol Pharm,2016,13(4):1413-1429.
13. Perez-Lopez R,Lorente D,Blackledge M D,et al.Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer[J].Radiology,2016,280(1):151-160.
14. Gdowski A S,Ranjan A,Sarker M R,et al.Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesion and pain[J].Nanomedicine(Lond),2017,12(17):2083-2095.
15. ZHANG Miao,HE Yao.Preparation and quality evaluation of cabazitaxel nanosuspension[J].China Pharmacist,2018,21(7):1167-1171.In Chinese with English abstract.
16. Bteich J,McManus S A,Ernsting M J,et al.Using flash nanoprecipitation to produce highly potent and stable cellax nanoparticles from amphiphilic polymers derived from carboxymethyl cellulose,polyethylene glycol and cabazitaxel[J]. Mol Pharm,2017,14(11):3998-4007.
17. LIU Yang,XIE Bin,LI Lin,et al.PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability,bioavailability,antitumor efficacy and toxicity[J]. Drug Deliv Transl Res,2018,8(5):1365-1379.
18. CHEN Weijun,GUO Miao,WANG Shuli.Anti prostate cancer using PEGylated bombesin containing,cabazitaxel loading nano-sized drug delivery system[J].Drug Dev Ind Pharm,2016,42(12):1968-1976.
19. ZHANG Haijun,WANG Yingjie,LIU Liucheng.Study on the preparation,quality control and stability of cabazitaxel liposomes[J].Chin J Integr Med Cardio,2017,15(7):805-808.In Chinese.
20. ZHANG Li,LI Yaping,CHEN Lingli.Preparation of cabazitaxel liposomes and its pharmacokinetics in rats[J].Chin J Pharm,2017,48(6):874-878.In Chinese.
21. WANG Mengdi,HE Guangwei.Progress in targeting drug delivery system of albumin nanoparticles[J].Anhui Med Pharm J,2013,17(10):1649-1651.In Chinese with English abstract.
22. QU Na,Lee R J,SUN Yating,et al.Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer[J].Int J Nanomed,2016,11:3451-3459.
23. Qu N,Sun Y,Xie J,et al.Preparation and evaluation of in vitro self-assembling HSA nanoparticles for cabazitaxel[J].Anticancer Agents Med Chem,2017,17(2):294-300.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口